You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Life & Medical Care

Global and China Myasthenia Gravis Drugs Market Insights, Forecast to 2026

Market Analysis and Insights: Global and China Myasthenia Gravis Drugs Market
This report focuses on global and China Myasthenia Gravis Drugs LBI Global and China market.
The global Myasthenia Gravis Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

Global Myasthenia Gravis Drugs Scope and Market Size
Myasthenia Gravis Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Myasthenia Gravis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Myasthenia Gravis Drugs market is segmented into
Anticholinesterases
Immunosuppressants
Intravenous Immune Globulins

Segment by Application, the Myasthenia Gravis Drugs market is segmented into
Hospitals
Clinics

Regional and Country-level Analysis
The Myasthenia Gravis Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Myasthenia Gravis Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Myasthenia Gravis Drugs Market Share Analysis
Myasthenia Gravis Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Myasthenia Gravis Drugs business, the date to enter into the Myasthenia Gravis Drugs market, Myasthenia Gravis Drugs product introduction, recent developments, etc.
The major vendors covered:
Flamel Technologies
F. Hoffmann-La Roche
Grifols
Pfizer
Takeda
Novartis
Bausch Health
Alexion Pharmaceuticals
Catalyst Pharmaceuticals
CSL
Curavac
Cytokinetics
Galencia
GlaxoSmithKline
Lupin Pharmaceuticals
Mitsubishi Tanabe Pharma
1 Study Coverage
1.1 Myasthenia Gravis Drugs Product Introduction
1.2 Market Segments
1.3 Key Myasthenia Gravis Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Myasthenia Gravis Drugs Market Size Growth Rate by Type
1.4.2 Anticholinesterases
1.4.3 Immunosuppressants
1.4.4 Intravenous Immune Globulins
1.5 Market by Application
1.5.1 Global Myasthenia Gravis Drugs Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Clinics
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Myasthenia Gravis Drugs Market Size, Estimates and Forecasts
2.1.1 Global Myasthenia Gravis Drugs Revenue 2015-2026
2.1.2 Global Myasthenia Gravis Drugs Sales 2015-2026
2.2 Global Myasthenia Gravis Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 Myasthenia Gravis Drugs Historical Market Size by Region (2015-2020)
2.3.1 Global Myasthenia Gravis Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global Myasthenia Gravis Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 Myasthenia Gravis Drugs Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Myasthenia Gravis Drugs Sales Forecast by Region (2021-2026)
2.4.2 Global Myasthenia Gravis Drugs Revenue Forecast by Region (2021-2026)

3 Global Myasthenia Gravis Drugs Competitor Landscape by Players
3.1 Global Top Myasthenia Gravis Drugs Sales by Manufacturers
3.1.1 Global Myasthenia Gravis Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Myasthenia Gravis Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Global Myasthenia Gravis Drugs Manufacturers by Revenue
3.2.1 Global Myasthenia Gravis Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Myasthenia Gravis Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Myasthenia Gravis Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Myasthenia Gravis Drugs Revenue in 2019
3.2.5 Global Myasthenia Gravis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Myasthenia Gravis Drugs Price by Manufacturers
3.4 Global Myasthenia Gravis Drugs Manufacturing Base Distribution, Product Types
3.4.1 Myasthenia Gravis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Myasthenia Gravis Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Myasthenia Gravis Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Myasthenia Gravis Drugs Market Size by Type (2015-2020)
4.1.1 Global Myasthenia Gravis Drugs Sales by Type (2015-2020)
4.1.2 Global Myasthenia Gravis Drugs Revenue by Type (2015-2020)
4.1.3 Myasthenia Gravis Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Myasthenia Gravis Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Myasthenia Gravis Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Myasthenia Gravis Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Myasthenia Gravis Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Myasthenia Gravis Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Myasthenia Gravis Drugs Market Size by Application (2015-2020)
5.1.1 Global Myasthenia Gravis Drugs Sales by Application (2015-2020)
5.1.2 Global Myasthenia Gravis Drugs Revenue by Application (2015-2020)
5.1.3 Myasthenia Gravis Drugs Price by Application (2015-2020)
5.2 Myasthenia Gravis Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Myasthenia Gravis Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Myasthenia Gravis Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Myasthenia Gravis Drugs Price Forecast by Application (2021-2026)

6 China by Players, Type and Application
6.1 China Myasthenia Gravis Drugs Market Size YoY Growth 2015-2026
6.1.1 China Myasthenia Gravis Drugs Sales YoY Growth 2015-2026
6.1.2 China Myasthenia Gravis Drugs Revenue YoY Growth 2015-2026
6.1.3 China Myasthenia Gravis Drugs Market Share in Global Market 2015-2026
6.2 China Myasthenia Gravis Drugs Market Size by Players (International and Local Players)
6.2.1 China Top Myasthenia Gravis Drugs Players by Sales (2015-2020)
6.2.2 China Top Myasthenia Gravis Drugs Players by Revenue (2015-2020)
6.3 China Myasthenia Gravis Drugs Historic Market Review by Type (2015-2020)
6.3.1 China Myasthenia Gravis Drugs Sales Market Share by Type (2015-2020)
6.3.2 China Myasthenia Gravis Drugs Revenue Market Share by Type (2015-2020)
6.3.3 China Myasthenia Gravis Drugs Price by Type (2015-2020)
6.4 China Myasthenia Gravis Drugs Market Estimates and Forecasts by Type (2021-2026)
6.4.1 China Myasthenia Gravis Drugs Sales Forecast by Type (2021-2026)
6.4.2 China Myasthenia Gravis Drugs Revenue Forecast by Type (2021-2026)
6.4.3 China Myasthenia Gravis Drugs Price Forecast by Type (2021-2026)
6.5 China Myasthenia Gravis Drugs Historic Market Review by Application (2015-2020)
6.5.1 China Myasthenia Gravis Drugs Sales Market Share by Application (2015-2020)
6.5.2 China Myasthenia Gravis Drugs Revenue Market Share by Application (2015-2020)
6.5.3 China Myasthenia Gravis Drugs Price by Application (2015-2020)
6.6 China Myasthenia Gravis Drugs Market Estimates and Forecasts by Application (2021-2026)
6.6.1 China Myasthenia Gravis Drugs Sales Forecast by Application (2021-2026)
6.6.2 China Myasthenia Gravis Drugs Revenue Forecast by Application (2021-2026)
6.6.3 China Myasthenia Gravis Drugs Price Forecast by Application (2021-2026)

7 North America
7.1 North America Myasthenia Gravis Drugs Market Size YoY Growth 2015-2026
7.2 North America Myasthenia Gravis Drugs Market Facts & Figures by Country
7.2.1 North America Myasthenia Gravis Drugs Sales by Country (2015-2020)
7.2.2 North America Myasthenia Gravis Drugs Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada

8 Europe
8.1 Europe Myasthenia Gravis Drugs Market Size YoY Growth 2015-2026
8.2 Europe Myasthenia Gravis Drugs Market Facts & Figures by Country
8.2.1 Europe Myasthenia Gravis Drugs Sales by Country
8.2.2 Europe Myasthenia Gravis Drugs Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia

9 Asia Pacific
9.1 Asia Pacific Myasthenia Gravis Drugs Market Size YoY Growth 2015-2026
9.2 Asia Pacific Myasthenia Gravis Drugs Market Facts & Figures by Country
9.2.1 Asia Pacific Myasthenia Gravis Drugs Sales by Region (2015-2020)
9.2.2 Asia Pacific Myasthenia Gravis Drugs Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam

10 Latin America
10.1 Latin America Myasthenia Gravis Drugs Market Size YoY Growth 2015-2026
10.2 Latin America Myasthenia Gravis Drugs Market Facts & Figures by Country
10.2.1 Latin America Myasthenia Gravis Drugs Sales by Country
10.2.2 Latin America Myasthenia Gravis Drugs Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina

11 Middle East and Africa
11.1 Middle East and Africa Myasthenia Gravis Drugs Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Myasthenia Gravis Drugs Market Facts & Figures by Country
11.2.1 Middle East and Africa Myasthenia Gravis Drugs Sales by Country
11.2.2 Middle East and Africa Myasthenia Gravis Drugs Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E

12 Company Profiles
12.1 Flamel Technologies
12.1.1 Flamel Technologies Corporation Information
12.1.2 Flamel Technologies Description and Business Overview
12.1.3 Flamel Technologies Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Flamel Technologies Myasthenia Gravis Drugs Products Offered
12.1.5 Flamel Technologies Recent Development
12.2 F. Hoffmann-La Roche
12.2.1 F. Hoffmann-La Roche Corporation Information
12.2.2 F. Hoffmann-La Roche Description and Business Overview
12.2.3 F. Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
12.2.4 F. Hoffmann-La Roche Myasthenia Gravis Drugs Products Offered
12.2.5 F. Hoffmann-La Roche Recent Development
12.3 Grifols
12.3.1 Grifols Corporation Information
12.3.2 Grifols Description and Business Overview
12.3.3 Grifols Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Grifols Myasthenia Gravis Drugs Products Offered
12.3.5 Grifols Recent Development
12.4 Pfizer
12.4.1 Pfizer Corporation Information
12.4.2 Pfizer Description and Business Overview
12.4.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Pfizer Myasthenia Gravis Drugs Products Offered
12.4.5 Pfizer Recent Development
12.5 Takeda
12.5.1 Takeda Corporation Information
12.5.2 Takeda Description and Business Overview
12.5.3 Takeda Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Takeda Myasthenia Gravis Drugs Products Offered
12.5.5 Takeda Recent Development
12.6 Novartis
12.6.1 Novartis Corporation Information
12.6.2 Novartis Description and Business Overview
12.6.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Novartis Myasthenia Gravis Drugs Products Offered
12.6.5 Novartis Recent Development
12.7 Bausch Health
12.7.1 Bausch Health Corporation Information
12.7.2 Bausch Health Description and Business Overview
12.7.3 Bausch Health Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Bausch Health Myasthenia Gravis Drugs Products Offered
12.7.5 Bausch Health Recent Development
12.8 Alexion Pharmaceuticals
12.8.1 Alexion Pharmaceuticals Corporation Information
12.8.2 Alexion Pharmaceuticals Description and Business Overview
12.8.3 Alexion Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Alexion Pharmaceuticals Myasthenia Gravis Drugs Products Offered
12.8.5 Alexion Pharmaceuticals Recent Development
12.9 Catalyst Pharmaceuticals
12.9.1 Catalyst Pharmaceuticals Corporation Information
12.9.2 Catalyst Pharmaceuticals Description and Business Overview
12.9.3 Catalyst Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Products Offered
12.9.5 Catalyst Pharmaceuticals Recent Development
12.10 CSL
12.10.1 CSL Corporation Information
12.10.2 CSL Description and Business Overview
12.10.3 CSL Sales, Revenue and Gross Margin (2015-2020)
12.10.4 CSL Myasthenia Gravis Drugs Products Offered
12.10.5 CSL Recent Development
12.11 Flamel Technologies
12.11.1 Flamel Technologies Corporation Information
12.11.2 Flamel Technologies Description and Business Overview
12.11.3 Flamel Technologies Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Flamel Technologies Myasthenia Gravis Drugs Products Offered
12.11.5 Flamel Technologies Recent Development
12.12 Cytokinetics
12.12.1 Cytokinetics Corporation Information
12.12.2 Cytokinetics Description and Business Overview
12.12.3 Cytokinetics Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Cytokinetics Products Offered
12.12.5 Cytokinetics Recent Development
12.13 Galencia
12.13.1 Galencia Corporation Information
12.13.2 Galencia Description and Business Overview
12.13.3 Galencia Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Galencia Products Offered
12.13.5 Galencia Recent Development
12.14 GlaxoSmithKline
12.14.1 GlaxoSmithKline Corporation Information
12.14.2 GlaxoSmithKline Description and Business Overview
12.14.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
12.14.4 GlaxoSmithKline Products Offered
12.14.5 GlaxoSmithKline Recent Development
12.15 Lupin Pharmaceuticals
12.15.1 Lupin Pharmaceuticals Corporation Information
12.15.2 Lupin Pharmaceuticals Description and Business Overview
12.15.3 Lupin Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Lupin Pharmaceuticals Products Offered
12.15.5 Lupin Pharmaceuticals Recent Development
12.16 Mitsubishi Tanabe Pharma
12.16.1 Mitsubishi Tanabe Pharma Corporation Information
12.16.2 Mitsubishi Tanabe Pharma Description and Business Overview
12.16.3 Mitsubishi Tanabe Pharma Sales, Revenue and Gross Margin (2015-2020)
12.16.4 Mitsubishi Tanabe Pharma Products Offered
12.16.5 Mitsubishi Tanabe Pharma Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Myasthenia Gravis Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Myasthenia Gravis Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
  • FORMAT: PDF
  • PUBLISHED DATE: Aug, 2020
  • NO OF PAGES: 134